FOLH1 and neoplasm: In the largest monocentric study to date, the whole-body parameter TLP, derived by PSMA-PET/CT and reflecting the total viable tumor burden, is shown to be a prognostic PET biomarker for mCRPC patients undergoing [177Lu]Lu-PSMA-617 RLT, with its change after 2 treatment cycles predicting overall survival.